Tecnimede Group and Finnish Red Cross Blood Service partner to develop advanced therapy medicinal products
Tecnimede Group and the Finnish Red Cross Blood Service (FRCBS) have signed a collaboration agreement to jointly develop advanced therapy medicinal products (ATMPs) for cancer treatments. The aim of the cooperation is to introduce new treatment options, particularly for patients whose condition does not respond sufficiently well to current treatments.
The partnership combines FRCBS’s scientific expertise in cell therapy development and clinical translation, supported by specialised infrastructure and technology platforms, with Tecnimede’s pharmaceutical development capabilities and experience in bringing medicines to patients.
For Tecnimede, the collaboration strengthens its innovation strategy, expands its capabilities in advanced therapies and complements its existing ATMP development pipeline. For FRCBS, it creates a further opportunity to apply its scientific and technological expertise to the development of new therapeutic options through collaboration with an industry partner.
The organisations aim to advance promising cell therapies from preclinical development towards clinical evaluation, laying the groundwork for future treatments for patients with limited therapeutic options.
More information:
João Serra, Joao.Serra@tecnimede.com, Tecnimede Group
Helka Göös, helka.goos@veripalvelu.fi, Finnish Red Cross Blood Service
Tecnimede Group is a privately owned Portuguese pharmaceutical group founded in 1980 and dedicated to the research, development, manufacturing and commercialisation of medicinal products for human use. The Group combines a portfolio of innovative and generic medicines with in-house R&D expertise and manufacturing capabilities, reaching more than 100 countries worldwide. Its mission is to combine medical science and technology to sustainably improve living standards and foster shared prosperity in the communities we serve worldwide.
The Finnish Red Cross Blood Service is responsible for the supply of blood products throughout Finland and for the laboratory services that support this. It also provides services to the healthcare sector, such as those supporting stem cell and organ transplants, as well as products used in new cell therapy treatments. The Blood Service is a not-for-profit organisation.